Jazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda For $95M

Jazz Pharmaceuticals JAZZ today announced the closing of the sale of its women's health business to Meda (an international specialty pharmaceutical company) for $95 million in cash. The products included in the sale are Elestrin® (estradiol gel), Gastrocrom® (cromolyn sodium, USP), Natelle® One (prenatal vitamin), AVC™ Cream (sulfanilamide), Gesticare® DHA (prenatal multi-vitamin) and Urelle® (urinary antiseptic). For accounting purposes, the women's health business will be treated as a discontinued operation. More detail about the accounting impact of the transaction will be disclosed in pro forma financial statements filed on a Form 8-K and in the company's Form 10-Q for the quarter ended September 30, 2012.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsAsset Sales
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!